If you've researched GLP-1 medications, you've probably noticed something confusing: Ozempic and Wegovy both contain semaglutide, both are made by Novo Nordisk, both are weekly injections, yet they're marketed as different drugs with different prices and different prescribing rules. What gives?
The answer matters because choosing between them (or being prescribed one over the other) affects your eligibility, your insurance coverage, and your out-of-pocket cost. Here's a clear breakdown.
The Short Answer
Ozempic is FDA-approved for type 2 diabetes. Wegovy is FDA-approved for chronic weight management. Both contain the same active ingredient (semaglutide) at different maximum doses, packaged in different pens, with different official indications.
From a pharmacological standpoint, they are the same molecule. From a regulatory and insurance standpoint, they are different products.
Wegovy vs Ozempic at a Glance
| Feature | Ozempic | Wegovy |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA-approved use | Type 2 diabetes | Chronic weight management |
| Maximum weekly dose | 2.0 mg | 2.4 mg |
| Dose strengths | 0.25, 0.5, 1.0, 2.0 mg | 0.25, 0.5, 1.0, 1.7, 2.4 mg |
| Form | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Approval year | 2017 | 2021 |
| List price (2026, no insurance) | ~$1,000/month | ~$1,350/month |
| Typical insurance posture | Often covered for T2D | Often denied or heavy prior authorization for weight loss |
| Cardiovascular approval | Risk reduction in T2D | Risk reduction in overweight/obesity with established CVD |
The single most important row in that table is the FDA-approved use. Everything else, the price, the coverage rules, the dose ceiling, follows from the indication each product is labeled for.
The Key Differences
*FDA Indication:*
*Maximum Dose:*
*Approval Year:*
*Pricing (2026, brand-name list price):*
*Insurance Coverage:*
Why Doctors Prescribe Ozempic Off-Label for Weight Loss
Because Ozempic and Wegovy are pharmacologically nearly identical, many physicians prescribe Ozempic off-label for weight loss, particularly when a patient's insurance covers Ozempic but not Wegovy. This is legal and clinically reasonable, though it has contributed to the well-documented Ozempic shortages of recent years.
The trade-off: Ozempic's max dose (2.0mg) is slightly lower than Wegovy's (2.4mg), so patients who need the higher therapeutic dose for weight management may not reach their goal weight as efficiently.
How Semaglutide Is Titrated
Both Ozempic and Wegovy follow a gradual dose-escalation schedule. The slow ramp is deliberate, it gives the digestive system time to adjust and reduces the nausea that most often appears in the first weeks. A typical weight-management titration for semaglutide looks like this, always under physician direction:
Your prescriber may move slower than this if side effects appear, hold you at a dose that is working, or stop escalating once you reach an effective dose. The lowest dose that produces results is the right dose, there is no clinical benefit to climbing higher than you need.
Side Effects: What to Expect
Because Ozempic and Wegovy are the same molecule, their side-effect profiles are essentially identical. The most common effects are gastrointestinal and tend to ease as the body adjusts:
Semaglutide carries a boxed warning regarding the risk of thyroid C-cell tumors based on rodent studies, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Less common but serious risks include pancreatitis, gallbladder problems, and kidney injury from dehydration. This is general information, not medical advice. A licensed physician reviews your history before prescribing and is the right person to weigh these risks for you.
Switching Between Ozempic and Wegovy
Patients switch between the two products more often than people expect, usually for one of three reasons: an insurance change, a supply shortage of one product, or a shift in goal from blood-sugar control to weight management. Because the active ingredient is the same, a switch is generally straightforward, but it is a prescriber decision, not a do-it-yourself change.
The practical issue is that the two pens deliver different dose strengths and titration steps, so matching your current weekly dose on the new device requires care. A physician will typically map you to the closest available dose, then resume titration from there. The most common avoidable mistake is a patient assuming the dose dials are interchangeable between the two products. They are not.
What Changed in 2026
The Wegovy vs Ozempic decision looks different in 2026 than it did even a year ago, and three shifts matter for cost and access.
First, brand-name access loosened on the supply side. After years of intermittent shortages, semaglutide came off the FDA shortage list, which tightened the rules around large-scale compounding of the molecule. That single regulatory change reshaped the lower-cost market that many patients had relied on.
Second, the brand manufacturer leaned into direct-to-consumer cash pricing. Novo Nordisk expanded self-pay channels for Wegovy, pulling the effective monthly cash price down from the roughly $1,350 list figure toward a lower self-pay band for patients without coverage. Ozempic remains labeled and priced for diabetes, so insurance still drives most of its real-world cost.
Third, the compounded market consolidated. Several large telehealth players exited compounded semaglutide in early 2026 as the shortage ended and legal pressure increased, narrowing the field to providers that work with licensed 503A and 503B pharmacies under individual physician prescriptions. For a patient choosing today, that means the practical question is less "Wegovy or Ozempic" in isolation and more "brand-name semaglutide through insurance, brand-name through cash pay, or compounded semaglutide through a reputable physician-led provider."
What the Clinical Trials Show
STEP-1 (NEJM, 2021), the foundational trial for Wegovy, showed average weight loss of approximately 14.9% of body weight at 68 weeks with semaglutide 2.4mg in non-diabetic adults with overweight or obesity.
SUSTAIN trials for Ozempic in type 2 diabetes patients showed average weight loss of approximately 6–10% at lower doses, though weight loss was a secondary endpoint.
SELECT trial (NEJM, 2023) showed semaglutide 2.4mg reduced major adverse cardiovascular events by 20% in patients with overweight/obesity and established CVD over a mean ~40-month follow-up.
Results may vary.
Compounded Semaglutide: The Third Option
When the FDA places semaglutide on its drug shortage list, state-licensed compounding pharmacies may legally prepare semaglutide formulations. Compounded semaglutide:
For patients without insurance coverage for brand-name semaglutide, compounded semaglutide is often the most accessible option.
Which One Is Right for You?
*Choose Ozempic if:*
*Choose Wegovy if:*
*Consider compounded semaglutide if:*
What Majesta Health Offers
At Majesta Health, we provide compounded semaglutide through licensed, FDA-registered 503A compounding pharmacies, with board-certified physician oversight. Start your 2-minute medical assessment at /quiz to see if you qualify.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider. Individual results may vary.
<!-- related-2026-injected -->
Related 2026 guides
Frequently Asked Questions
Wegovy vs Ozempic: are they the same drug?
Wegovy and Ozempic are not the same product, but they contain the same active ingredient, semaglutide, and are both made by Novo Nordisk. They are sold as separate medications because they carry different FDA-approved indications, different maximum doses, and different pen devices. Ozempic is approved for type 2 diabetes at up to 2.0 mg per week. Wegovy is approved for chronic weight management at up to 2.4 mg per week. The molecule is identical, the labeled use, the dose ceiling, and the price are what differ.
Can I switch from Ozempic to Wegovy?
Switching between Ozempic and Wegovy is a clinical decision made by your prescriber, because while both are semaglutide, the available dose strengths and titration steps differ between the two pens. A physician will usually match your current weekly dose as closely as possible and then continue titration on the new product. Do not switch on your own without prescriber guidance, since dosing errors between the two devices are the most common avoidable problem when changing products.
What is the actual difference between Ozempic and Wegovy?
Ozempic and Wegovy are both made by Novo Nordisk and both contain the same active ingredient, semaglutide. The differences are FDA-approved use, available doses, and packaging. Ozempic is FDA-approved for type 2 diabetes at doses of 0.25, 0.5, 1.0, and 2.0 mg per week. Wegovy is FDA-approved for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher with at least one weight-related condition), at doses up to 2.4 mg per week. Both are weekly subcutaneous injections. The medicine inside is the same molecule, the labeled use and dose ceiling are what differ.
Why does Wegovy cost more than Ozempic if they are the same drug?
Wegovy is priced higher because it carries the FDA approval for chronic weight management and is dosed at the higher 2.4 mg ceiling, while Ozempic is priced and labeled for diabetes. Without insurance, Wegovy lists around $1,349 a month at retail and Ozempic around $1,029 a month. Insurance often covers Ozempic for type 2 diabetes patients but is more restrictive on Wegovy for weight loss. This pricing gap is also why many patients turn to compounded semaglutide, which uses the same active ingredient and is prescribed by US-licensed physicians at a fraction of the retail price for either brand.
Can you take Ozempic for weight loss instead of Wegovy?
Ozempic is sometimes prescribed off-label for weight loss when a physician determines it is clinically appropriate, but it is FDA-approved only for type 2 diabetes. Off-label prescribing is legal in the United States and common in medicine, however insurance is unlikely to cover Ozempic for weight loss because the labeled indication is diabetes. Wegovy is the FDA-approved semaglutide for weight management and is the standard of care for that indication when affordable and available.
Is compounded semaglutide the same as Ozempic or Wegovy?
Compounded semaglutide uses the same active ingredient (semaglutide) as Ozempic and Wegovy but is not the same final product. Brand-name Ozempic and Wegovy are FDA-approved finished drugs manufactured by Novo Nordisk under specific commercial formulations. Compounded semaglutide is prepared by a state-licensed compounding pharmacy under a physician prescription for an individual patient. Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient is FDA-registered.
Which is more effective for weight loss, Ozempic or Wegovy?
Wegovy is more effective for weight loss on average because it is approved and dosed to 2.4 mg per week, the dose that produced an average 14.9% body weight reduction at week 68 in the STEP-1 trial (NEJM 2021). Ozempic tops out at 2.0 mg per week and was studied primarily for glycemic control rather than weight loss outcomes. For patients whose primary goal is weight reduction, Wegovy or compounded semaglutide dosed to the weight-management range under physician supervision are the appropriate choices.
All Majesta Health medical content is clinically reviewed before publication by US-licensed physicians affiliated with our clinical infrastructure partner, MD Integrations (MDI). Reviewers hold active state medical licenses, are board-certified in primary care or obesity medicine, and specialize in GLP-1 receptor agonist therapy for chronic weight management. MDI is LegitScript certified and SOC 2 Type II accredited.
- US-licensed physicians affiliated with our clinical partner MD Integrations (LegitScript certified, HIPAA, SOC 2 Type II, ISO certified)
- Board-certified in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across all 50 US states and DC through the MD Integrations Medical Services Organization
- Dispensing pharmacy partner: Belmar Pharma Solutions (LegitScript certified, NABP accredited, 503A and 503B compounding)